Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous QLB for Pain After Hepatic Surgery
NCT02914015Terminated
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, single-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms). Primary endpoint: Cumulative morphine consumption at 24 hours. Started Aug 2018; status: terminated.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02914015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914015.